The ALDH1A1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ALDH1A1 locus in the widely used HeLa human cervical adenocarcinoma cell line. As a polyclonal pool, this model captures the genetic variation inherent in a mixed population of edited cells, enabling robust analysis of ALDH1A1 loss-of-function without the biases introduced by single-cell cloning. The knockout disrupts retinoic acid synthesis, providing a versatile tool for dissecting retinoid signaling pathways in a cancer-relevant context.
HeLa cells, derived from a human cervical adenocarcinoma and positive for HPV-18, are among the most extensively employed epithelial cell lines in biomedical research. Their immortality and well-characterized oncogenic properties make them an ideal host for studying cell cycle control, apoptosis, and stress responses. In particular, HeLa cells exhibit active retinoic acid metabolism and express ALDH1A1, rendering them a relevant platform for interrogating the role of this enzyme in cancer cell biology.
ALDH1A1 encodes a cytosolic aldehyde dehydrogenase that irreversibly oxidizes retinaldehyde to all-trans-retinoic acid (ATRA) using NAD+ as a cofactor. ATRA serves as a ligand for nuclear retinoic acid receptors (RAR??, RAR??, RAR??) which heterodimerize with retinoid X receptors (RXR) to regulate gene transcription. The ALDH1A1-driven pathway is modulated by upstream signals including C/EBP??, STAT3, Wnt/??-catenin, and TGF-??, and it controls downstream targets such as HOX genes, CYP26A1, RAR??, and p21Cip1. Additionally, retinoic acid-binding proteins (CRABP) fine-tune the availability of ATRA. Through this network, ALDH1A1 influences stem cell maintenance, differentiation, and responses to oxidative and chemotherapeutic stress.
In the HeLa background, ALDH1A1 knockout allows researchers to dissect the enzyme??s contribution to cancer stem cell phenotypes and drug resistance. Without ALDH1A1-mediated retinoic acid production, HeLa cells exhibit altered differentiation programs and may become more susceptible to stress, providing a model to study the molecular basis of retinoid signaling in oncogenesis. This polyclonal knockout model is particularly useful for linking ALDH1A1 activity to cellular proliferation, differentiation markers, and chemosensitivity in a cervical adenocarcinoma context.
Typical applications include cancer stem cell biology, where the ALDEFLUOR assay can measure ALDH activity, and drug resistance studies employing chemotherapeutic agents. Researchers can quantify retinoic acid levels by LC-MS, assess ALDH1A1 protein expression by western blot, and profile downstream gene expression changes via RT-qPCR for targets such as CYP26A1. High-throughput approaches like RNA-seq enable comprehensive pathway analysis. This knockout cell population is a valuable asset for differentiation therapy research and toxicology screens investigating retinoid metabolism. For further inquiries, please contact Ascent Research.
